Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Newell

Showing results (411-420 of 519) with videos related to

Pageof 52
Sort By:
Clinical Pharmacology and Therapeutics|April 1, 1996
Population pharmacokinetics of carboplatin in childrenE Chatelut, A V Boddy, B Peng, et al.
Organic & Biomolecular Chemistry|April 11, 2015
Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatasesDuncan C Miller, Benoit Carbain, Gary S Beale, et al.
Hematological Oncology|January 1, 1990
The myelotoxicity of carboplatin is influenced by the time of its administrationD J Kerr, C Lewis, B O'Neil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapyG J Veal, C Dias, L Price, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)M J Millward, D R Newell, V Mummaneni, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2016
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037Emma J Haagensen, Huw D Thomas, Wolfgang A Schmalix, et al.
Plos One|December 17, 2013
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing miceEmma J Haagensen, Huw D Thomas, Ian Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancerM J Millward, D R Newell, K Yuen, et al.
Vaccine|September 4, 2024
Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculatorCarissa Bonner, Melody Taba, Michael Anthony Fajardo, et al.
Pageof 52

Showing results (411-420 of 519) with videos related to

Sort By:
Pageof 52
Clinical Pharmacology and Therapeutics|April 1, 1996
Population pharmacokinetics of carboplatin in childrenE Chatelut, A V Boddy, B Peng, et al.
Organic & Biomolecular Chemistry|April 11, 2015
Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatasesDuncan C Miller, Benoit Carbain, Gary S Beale, et al.
Hematological Oncology|January 1, 1990
The myelotoxicity of carboplatin is influenced by the time of its administrationD J Kerr, C Lewis, B O'Neil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapyG J Veal, C Dias, L Price, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)M J Millward, D R Newell, V Mummaneni, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2016
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037Emma J Haagensen, Huw D Thomas, Wolfgang A Schmalix, et al.
Plos One|December 17, 2013
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing miceEmma J Haagensen, Huw D Thomas, Ian Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancerM J Millward, D R Newell, K Yuen, et al.
Vaccine|September 4, 2024
Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculatorCarissa Bonner, Melody Taba, Michael Anthony Fajardo, et al.
Pageof 52